ADXN Earnings

ADXN reported its earnings on 2026-06-15, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ADXN's earnings announcement on 2026-06-15, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, ADXN's stock price tends to shift by an average of 1.02% in the 10 days leading up to earnings and -12.71% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate ADXN's annual revenue to reach 200.00K, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ADXN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ADXN's stock price typically moves by 1.02% in the 10 days before its earnings and -12.71% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of undefined and revenue of 200.00K.

The earnings call lacked critical financial details such as revenue, margins, and cash flow, making it difficult to assess financial performance. While there were positive operational updates on drug development, potential regulatory and strategic execution risks were highlighted. The absence of strategic initiatives, shareholder return plans, and financial metrics limits the ability to predict strong market movement. Without additional insights from the Q&A, the sentiment remains neutral.